Tharimmune (THAR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
27 Jan, 2026Executive summary
Supplement clarifies the independence status of two board nominees for the upcoming special meeting.
The supplement should be read alongside the original proxy statement dated January 16, 2026.
No changes are made to the proposals or voting process for the special meeting.
Voting matters and shareholder proposals
Stockholders will vote on the election of Ms. Jill E. Sommers and Mr. William Wiley as directors at the January 30, 2026 special meeting.
Voting instructions and proxy cards remain unchanged; prior votes do not require further action.
Board of directors and corporate governance
Board reviewed and confirmed the independence of nominees Jill E. Sommers and William Wiley per Nasdaq rules.
Both nominees are considered independent and eligible for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tharimmune
- All proposals, including director elections and equity plan amendment, were approved.THAR
EGM 20262 Feb 2026 - Shareholders to vote on director elections, equity issuances, and plan amendments at virtual meeting.THAR
Proxy Filing16 Jan 2026 - $2B shelf registration supports blockchain and biotech growth, following a $545M PIPE raise.THAR
Registration Filing9 Jan 2026 - Shareholders to vote on board expansion, equity issuances, and a 7M-share plan increase.THAR
Proxy Filing6 Jan 2026 - Shareholders to vote on new directors, warrant issuances, and a 7M-share equity plan increase.THAR
Proxy Filing16 Dec 2025 - Raised $545M for a digital asset treasury strategy; offering is secondary, no new capital raised.THAR
Registration Filing16 Dec 2025 - Biotech registers 1.44M shares for resale from $2.02M private placement, funding R&D.THAR
Registration Filing16 Dec 2025 - Biotech registers 1M+ shares for resale after $2.08M private placement, funding R&D amid risks.THAR
Registration Filing16 Dec 2025 - Registering 4.2M shares for resale, with proceeds from warrants funding R&D amid Nasdaq compliance risk.THAR
Registration Filing16 Dec 2025